Weekly Funding Opportunities

[Med Research]

American Occupational Therapy Foundation: Health Services Research Grants Program<https://www.aotf.org/Grants/Health-Services-Research-Grant>
The American Occupational Therapy Foundation awards Health Services Research Grants as part of its mission to advance the science of occupational therapy to support people's full participation in meaningful life activities. Health Services Research (HSR) examines how people get access to health care, how and what care is delivered, the cost of that care, and what happens to patients as a result of receiving or not receiving care.  Specifically, HSR is a multidisciplinary field that studies how social factors, financing systems, organizational structures and processes, health technologies, and personal behaviors affect access to health care, the quality and costs of health care, and ultimately, the health and well-being of health care consumers. Health Services Research has a high value to both individuals and society. Past research has yielded information on intervention trends and risk factors, outcome of treatments, and patterns of care.  It has established new health policies, led to significant discoveries, and to the development of new therapies.
HSR Pilot Study Option #1:
Includes pilot studies examining an occupational therapy-related question using data from administrative or healthcare dataset(s) (e.g. Medicare Administrative data, Health System Electronic Medical records). Funding Required: $100,000 per grant. These studies may run up to 2 years.
HSR Pilot Study Option #2:
Includes pilot studies examining a rehabilitation question using data from publicly available datasets (e.g., Health and Retirement Survey, National Health and Aging Trends Study, National Health and Nutrition Examination Survey, LTCFocus). Funding Required: $50,000 per grant. These studies may run up to 1 year.
Letter of intent due August 31, 2020. Med-RA deadline to receive draft documents: August 18.

Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-266.html>
The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their mechanisms of action and clinical applications for the treatment of many diseases, disorders, and conditions. Given the emphasis on innovation, little or no preliminary data are needed to apply under this FOA. Because of the need for a multidisciplinary approach, collaborations among basic researchers, translational science researchers, music intervention experts, other clinical researchers, music health professionals, and technology development researchers are encouraged. The FOA utilizes a phased R61/R33 funding mechanism to support mechanistic research and to evaluate the clinical relevance of music interventions. The R61 phase will provide funding to either investigate the biological mechanisms or behavioral processes underlying music interventions in relevant animal models, healthy human subjects, and/or clinical populations, or can be used to develop innovative technology or approaches to enhance music intervention research. The second R33 phase will provide support for further mechanistic investigations in human subjects or animal models, intervention development, or pilot clinical studies. The pilot clinical studies may focus on intervention optimization/refinement, feasibility, adherence, and/or identification of appropriate outcome measures to inform future clinical research. Transition from the R61 to the R33 phase of the award will depend on successful completion of pre-specified milestones established in the R61.
Due October 2, 2020; June 2, 2021; October 4, 2021; June 2, 2022; October 3, 2022; and June 02, 2023. Med-RA deadline to receive draft documents for October 2 due date: September 21.

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 / R01 Clinical Trials Not Allowed)
R21<https://grants.nih.gov/grants/guide/pa-files/PAR-20-277.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-20-276.html>
Through these funding opportunity announcements, the National Cancer Institute along with the National Human Genome Research Institute and National Institute of Dental and Craniofacial Research encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.
Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October 5 R01 standard date: September 22. Med-RA deadline to receive draft documents for October 16 R21 standard date: October 5.

Fertility Status as a Marker for Overall Health (R21 / R01 Clinical Trial Optional)
R21<https://grants.nih.gov/grants/guide/pa-files/par-20-282.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-20-281.html>
The purpose of these funding opportunities is to support research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. Advancing this premise will require substantive involvement of experts in reproductive health/fertility along with expert in another non-reproductive specialty appropriate to the area of overall health being investigated, for example, in other fields such as epidemiology, or the somatic disease in question. This FOA focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of the disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA.
Due October 19, 2020; June 19, 2021; February 19, 2022; October 19, 2022; and June 19, 2023. Med-RA deadline to receive draft documents for October 19 due date: October 6.

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R03 / R21 / R01 Clinical Trial Optional)
R03<https://grants.nih.gov/grants/guide/pa-files/par-20-257.html>
R21<https://grants.nih.gov/grants/guide/pa-files/PAR-20-255.html>
R01<https://grants.nih.gov/grants/guide/pa-files/par-20-254.html>
These Funding Opportunity Announcements invite applications that propose to study the ethical, legal and social implications of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.
Due October 19, 2020; February, 17 2021; June 17, 2021; October 19, 2021; February 17, 2022; June 17, 2022; October 19, 2022; February 17, 2023; and June 19, 2023. Med-RA deadline to receive draft documents for October 19 due date: October 6.

Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-040.html>
Through this Funding Opportunity Announcement, the National Cancer Institute and the National Institute on Aging  will promote research to advance the understanding of the mechanistic factors and cellular interactions during aging that contribute to cancer initiation. Collaborations are strongly encouraged between scientists in the fields of aging biology and cancer biology. Applications should address key questions regarding how hallmarks of aging that lead to impaired cellular activities (metabolic alterations, proteostasis, epigenetic changes, and DNA repair) and alterations in the microenvironment (inflammation and immunosenescence) contribute to the development and outgrowth of cancer-initiating cells.
Due October 27, 2020 and February 17, 2021. Med-RA deadline to receive draft documents for October 27 due date: October 14.

Biogen Medical Education, Patient Education, and Professional & Scientific Development Grants
Biogen considers requests across a variety of disease areas including:
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Lupus, Multiple Sclerosis, Ophthalmology, Parkinson’s Disease, and Spinal Muscular Atrophy.
Medical Education<https://grantsandgiving.biogen.com/content/gma-grants-office/en_us/gmsgo/grants/medical-education.html>
Funding to an eligible institution or organization to support independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
Patient Education<https://grantsandgiving.biogen.com/content/gma-grants-office/en_us/gmsgo/grants/patient-education.html>
Funding to an eligible institution or organization to support independent educational activities for patients or caregivers.
Professional & Scientific Development<https://grantsandgiving.biogen.com/content/gma-grants-office/en_us/gmsgo/grants/professional-scientific-development.html>
Financial contribution to provide training and development for medical professionals or researchers within Biogen’s therapeutic areas of interest.
November 1, 2020; February 15, 2021; and May 15, 2021. Med-RA deadline to receive draft documents for November 1 due date: October 20.

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-269.html>
This Funding Opportunity Announcement invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions.
Due November 10, 2020. Med-RA deadline to receive draft documents: October 28.

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-279.html>
The purpose of this Funding Opportunity Announcement is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new devices or existing devices approved for other indications. Applications may evaluate the mechanism of action of a device.
Due December 15, 2020; August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; and August 10, 2023. Med-RA deadline to receive draft documents for December 15 due date: December 2.

Elsa U. Pardee Foundation: Cancer Research Grants<https://pardeefoundation.org/how-to-apply/>
The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application.
Due December 31, 2020, April 30, 2021, August 31, 2021. Med-RA deadline to receive draft documents for December 31 due date: December 14.

Congressionally Directed Medical Research Programs
Combat Readiness – Medical Research Program<https://cdmrp.army.mil/funding/crrp>
Rapid Development and Translational Research Award
Pre-application (preproposal): September 10, 2020. Application: December 3, 2020.
Med-RA deadline to receive draft documents for preproposal due date: August 31.
Scleroderma Research Program<https://cdmrp.army.mil/funding/srp>
Idea Development Award
Pre-application (preproposal): September 9, 2020. Application: December 4, 2020.
Translational Research Partnership Award
Pre-application (preproposal): September 9, 2020. Application: December 4, 2020.
Med-RA deadline to receive draft documents for preproposal due date: August 31.

Forecast
Reducing Inequities in Cancer Outcomes through Community-Based Interventions on Social Determinants of Health<https://www.grants.gov/web/grants/view-opportunity.html?oppId=328316>
Estimated post date: December 2, 2020
Anticipated due date: February 10, 2021
The purpose of this CDC-ERA competition is to conduct evaluation research to build an evidence base of innovative, community-based interventions across multiple domains of social determinants of health to reduce racial and ethnic disparities in cancer outcomes. Evaluation research is defined as the systematic application of public health research procedures for assessing the conceptualization, design, implementation, effectiveness and utility of public health interventions. This research would advance our understanding of what works, for whom and why. Component A: Primary Cancer Prevention – to conduct evaluation research on an innovative, multi-sector intervention to reduce cancer risk in one or more socially or economically disadvantaged populations. This research will examine the implementation, impact, and causal mechanisms of the intervention’s effect to reduce cancer risk at the population level. Component B: Cancer Screening – to conduct evaluation research on an innovative, multi-sector intervention to reduce inequities in the receipt of appropriate screening services (on-time initial screening, routine re-screening at recommended intervals, appropriate follow-up after inconclusive/incomplete screening) among one or more socially or economically disadvantaged populations. This research will generate knowledge about the implementation, impact, and causal mechanisms of the intervention’s effect on cancer screening outcomes. Component C: Health and Wellbeing of Cancer Survivors – to conduct evaluation research on an innovative, multi-sector intervention to address barriers to health and well-being among cancer survivors from one or more socially or economically disadvantaged populations. This research will generate knowledge about the implementation, impact, and causal mechanisms of the intervention’s effect on the health and wellbeing of cancer survivors. Applicants may apply for one Component (Component A or Component B or Component C).

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200804/f0ffc7cd/attachment.html>